Last reviewed · How we verify
AGN-210961 Formulation 5
AGN-210961 Formulation 5 is a medication that targets the PCSK9 protein to lower LDL cholesterol.
AGN-210961 Formulation 5 is a medication that targets the PCSK9 protein to lower LDL cholesterol. Used for Hypercholesterolemia.
At a glance
| Generic name | AGN-210961 Formulation 5 |
|---|---|
| Sponsor | Allergan |
| Drug class | PCSK9 inhibitor |
| Target | PCSK9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By binding to PCSK9, AGN-210961 Formulation 5 inhibits the degradation of LDL receptors, leading to increased clearance of LDL cholesterol from the bloodstream. This results in a reduction of LDL cholesterol levels in the blood, which can help to slow the progression of atherosclerotic cardiovascular disease.
Approved indications
- Hypercholesterolemia
Common side effects
- Injection site reactions
- Musculoskeletal pain
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |